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Abstract Rho-associated coiled-coil kinase (ROCK) is a
major downstream effector of the small GTPase RhoA. The
ROCK family, consisting of ROCK1 and ROCK2, plays a
central role in the organization of the actin cytoskeleton,
and is involved in a wide range of fundamental cellular
functions such as contraction, adhesion, migration, prolif-
eration, and apoptosis. Since the discovery of effective
inhibitors such as fasudil and Y27632, the biological roles
of ROCK have been extensively explored in numerous
diseases, including cancer. Accumulating evidence sup-
ports the concept that ROCK plays important roles in
tumor development and progression through regulating
many key cellular functions associated with malignancy,
including tumorigenicity, tumor growth, metastasis,
angiogenesis, tumor cell apoptosis/survival and chemore-
sistance as well. This review focuses on the new advances
of the most recent 5 years from the studies on the roles of
ROCK in cancer development and progression; the dis-
cussion is mainly focused on the potential value of ROCK
inhibitors in cancer therapy.
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Abbreviations
ROCK Rho-associated coiled-coil kinase
PKA Protein kinase A
PKG Protein kinase G
PKC Protein kinase C
RBD Rho-binding domain
PH Pleckstrin homology
MLC Myosin light chain
siRNA Short interfering RNA
shRNA Short hairpin RNA
miRNA MicroRNA
EGF Epidermal growth factor
Introduction
Rho-associated coiled-coil kinase (ROCK) is one of the
best characterized effectors of the small GTPase RhoA and
belongs to the AGC family of serine/threonine protein
kinases, which also includes protein kinases A, G, and C
(PKA, PKG, PKC) (Ishizaki et al. 1996; Leung et al. 1996;
Matsui et al. 1996; Nakagawa et al. 1996). The ROCK
family consists of two isoforms, ROCK1 and ROCK2,
sharing 65 % overall homology and 92 % homology in the
kinase domain. Both kinases contain a catalytic kinase
domain at the N terminus followed by a central coiled-coil
domain, which includes the Rho-binding domain (RBD),
and a C-terminal pleckstrin-homology (PH) domain. The
primary roles of the ROCK family in the organization of
actin cytoskeleton have been well established, and they are
involved in a wide range of fundamental cellular functions
such as contraction, adhesion, migration, proliferation, and
apoptosis (Amano et al. 2010a; Julian and Olson 2014; Shi
and Wei 2007; Street and Bryan 2011). Since the discovery
of the ROCK family, the Rho/ROCK signaling pathway
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has attracted much attention in various research fields, and
more than 10,000 articles have been published; in partic-
ular, about 2000 articles are focused on Rho/ROCK
function in cancer. Accumulating evidence from basic and
clinical studies supports the concept that ROCK could be a
potential therapeutic target for diverse disorders, including
cardiovascular disorders, neurologic disorders, metabolic
disorders, and cancers (Huang et al. 2013; Knipe et al.
2015; Morgan-Fisher et al. 2013; Rath and Olson 2012;
Sawada and Liao 2014; Shi and Wei 2013; Watzlawick
et al. 2014).
The initiation and progression of cancer are multistep
events involving cellular transformation, tumor growth,
neovascularization, invasion, and metastasis. The roles of
ROCK in various cancer processes have been extensively
explored with a particular attention focused on tumor cell
motility, invasion, and metastasis (Chen et al. 2014; Kale
et al. 2015; Mali et al. 2014; Mardilovich et al. 2012;
Matsuoka and Yashiro 2014; Morgan-Fisher et al. 2013;
Rath and Olson 2012; Schofield and Bernard 2013). In
these studies, Y27632 (Uehata et al. 1997) and fasudil
(Asano et al. 1987), relatively selective ROCK inhibitors
which target the ATP-dependent kinase domain of ROCK1
and ROCK2, have been extensively used in dissecting their
roles in cellular signaling and animal disease models.
However, these inhibitors inhibit ROCK1 and ROCK2 with
similar potency (Breitenlechner et al. 2003; Davies et al.
2000; Ishizaki et al. 2000; Uehata et al. 1997), and cannot
be used to distinguish the functional differences between
ROCK1 and ROCK2. The specific disruption of each
ROCK isoform in mice offers a unique opportunity to
analyze in vivo physiological and pathological functions of
ROCK1 and ROCK2. This review focuses on the new
advances in exploring the roles of ROCK signaling in
cancer biology from the past 5 years and the discussion
mainly focuses on the potential value of ROCK inhibitors
as a novel anti-cancer approach in clinical therapy. Recent
findings derived from targeting ROCK1 and ROCK2 by
genetic approaches, short interfering RNA (siRNA) or
short hairpin RNA (shRNA)-based gene silencing tech-
niques, are also covered in the review.
Overview of ROCK Signaling Pathway
Substrates of ROCK
ROCK1 and ROCK2 share more than 30 immediate
downstream substrates due to the high degree of homology
in their kinase domains, and many of them are related to
the regulation of actin cytoskeleton and cell morphology
(Amano et al. 2010a; Morgan-Fisher et al. 2013; Schofield
and Bernard 2013; Shi and Wei 2007). The canonical
substrates of ROCK include myosin light chain (MLC)
(Amano et al. 1996; Kureishi et al. 1997), MLC phos-
phatase (Kawano et al. 1999; Kimura et al. 1996), LIM
kinase (Amano et al. 2001; Lin et al. 2003; Maekawa et al.
1999; Ohashi et al. 2000; Sumi et al. 2001), ezrin/radix-
in/moesin (Matsui et al. 1998), and adducin (Fukata et al.
1999). The consensus amino acid sequences which are
phosphorylated on these substrates are R/KXS/T or
R/KXXS/T (Kawano et al. 1999; Sumi et al. 2001).
However, these substrates can also be phosphorylated by
other serine-threonine kinases such as MLC kinase and
several other members of the AGC kinase family (Pearce
et al. 2010; Prudnikova et al. 2015). The ROCK/MLC
phosphatase/MLC and ROCK/LIM kinase/cofilin pathways
are profoundly involved in the regulation of actin filament
dynamics that are important for the regulation of cell
contractility, motility, and morphology. ROCK promotes
actomyosin contractility through increasing MLC phos-
phorylation, and stabilizes actin filaments through LIM
kinase activation, resulting in cofilin phosphorylation and
thereby inhibiting its actin-depolymerization activity.
Novel ROCK substrates are discovered constantly and
added to the list of the large cohort of substrates. A novel
substrate is elongation initiation factor-1-a-1, which was
found using a mutant ROCK2 containing a modified ATP
pocket to allow the use of selective ATP analogs, which are
not efficiently utilized by other protein kinases (Couzens
et al. 2014). Likewise, synthetic peptide substrates have
been developed for ROCK2, which can be used in mech-
anistic studies and drug development (Kang et al. 2011). In
the context of tumor cell migration, FilGAP, a GTPase
activating protein, is phosphorylated by ROCK in the
ameboid migration of carcinoma cells (Saito et al. 2012).
Moreover, a recent proteomic approach has identified 121
proteins as candidate substrates (Amano et al. 2010b;
Nishioka et al. 2012, 2015). Given the abundance of ROCK
substrates which are functionally diverse proteins, ROCK
proteins are involved in a wide range of fundamental cel-
lular functions such as contraction, adhesion, migration,
proliferation, and apoptosis as discussed below.
Regulation of ROCK Activity
ROCK exhibits auto-inhibitory activity (Amano et al.
1999); in its inactive form, the C-terminal PH domain and
RBD of ROCK interact with the kinase domain, which
forms an auto-inhibitory loop. ROCK activation occurs in
several ways: through interaction with common activators,
via alteration of subcellular localization, and by interaction
with isoform-specific regulatory molecules. The small Rho
GTPases, including RhoA, RhoB, and RhoC, are the most
deliberate ROCK regulators. Activated Rho directly inter-
acts with the RBD of ROCK and induces a conformational
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change initiating interactions of serine/threonine kinases
with selective substrates (Blumenstein and Ahmadian
2004; Fujisawa et al. 1996; Ishizaki et al. 1996; Leung
et al. 1996; Matsui et al. 1996; Nakagawa et al. 1996).
ROCK activity can also be modulated through interaction
of C-terminal PH domain with lipid mediators and with the
plasma membrane (Feng et al. 1999; Fu et al. 1998; Shirao
et al. 2002; Wen et al. 2008), auto-phosphorylation through
dimerization (Chuang et al. 2012; Couzens et al. 2009;
Doran et al. 2004; Dvorsky et al. 2004; Garg et al. 2008;
Jacobs et al. 2006; Yamaguchi et al. 2006), and proteolytic
cleavage of the inhibitory C-terminal domain (Coleman
et al. 2001; Sebbagh et al. 2001, 2005).
Other than common regulators such as RhoA/RhoB/
RhoC, ROCK1, and ROCK2 can also be individually
activated or inhibited by a number of positive or negative
regulators. The small GTP-binding protein RhoE interacts
with the N-terminal region of ROCK1 (amino acids 1–420)
and prevents Rho binding to RBD (Komander et al. 2008;
Ongusaha et al. 2006; Riento et al. 2003). Phosphoinosi-
tide-dependent protein kinase 1 selectively promotes
ROCK1 membrane translocation and blocks its association
with RhoE (Pinner and Sahai 2008). ROCK1 is cleaved by
caspase-3 at the cleavage site DETD1113 during apoptosis,
but this site is not present in ROCK2 (Coleman et al. 2001;
Sebbagh et al. 2001). On the other hand, during cytotoxic
lymphocyte granule-induced cell death, human ROCK2
can be cleaved by the proapoptotic protease granzyme B at
IGLD1131 site; however, the site is not present in ROCK1
(Sebbagh et al. 2005). Human ROCK2, but not ROCK1,
can be activated by caspase-2-dependent cleavage in
endothelial cells in response to thrombin, though the
cleavage site remains to be identified (Sapet et al. 2006).
ROCK2 activity can be negatively regulated through
interacting with coronin1A/B via its PH domain (Rana and
Worthylake 2012) and with collapsin response-mediator
protein 2 (Yoneda et al. 2012), or positively regulated
through interacting with nucleophosmin (Ferretti et al.
2010). Other studies have revealed that ROCK1 and
ROCK2 are phosphorylated by different kinases at multiple
sites which could apply various influences on their activi-
ties (Du and Hannon 2004; Lee et al. 2010; Lowery et al.
2007).
Many studies are focused on how the Rho/ROCK
pathway is associated with cancer progression. Increased
Rho/ROCK activity and/or gene expression have been
demonstrated in various types of cancers. In addition,
increased expression of ROCK protein or mRNA nega-
tively correlates with patient survival and positively with
the more advanced tumor stages and worse prognostics,
further supporting a contributory role of ROCK in cancer
progression (Abe et al. 2008; Gilkes et al. 2014; Lane et al.
2008; Li et al. 2015b; Wong et al. 2009; Zhang et al. 2015).
The factors attributable to the increased Rho/ROCK
activity and/or gene expression are context dependent. For
example, in responding to the hypoxic microenvironment,
hypoxia-inducible factors increase transcription of RhoA
and ROCK1 in breast cancer (Gilkes et al. 2014). In some
cases, Rho/ROCK activation is part of a downstream sig-
naling cascade: from SMAD4/TGF-b/BMP in colorectal
cancer (Voorneveld et al. 2014), vascular endothelial
growth factor in cervical cancer (He et al. 2010), androgen
in prostate cancer (Schmidt et al. 2012), chemokine
receptor 7 activation in metastatic squamous cell carci-
noma of the head and neck (Xu et al. 2015), epidermal
growth factor (EGF)/EGF receptor in pancreatic cancer
(Nakashima et al. 2011), and increased expression of the
receptor for activated C-kinase-1, a scaffolding protein,
interacting with RhoA to activate RhoA/ROCK pathway in
breast cancer (Cao et al. 2011). In some cases, Rho/ROCK
activation is due to the loss of an antagonist or inhibitor. In
hepatocellular carcinoma, the loss of the antagonist RhoE
leads to increased ROCK activity (Ma et al. 2013); in
invasive lobular carcinoma, p120-cadherin inhibits the
antagonist myosin phosphatase Rho-interacting protein
leading to increased Rho/ROCK activity (Schackmann
et al. 2011); in pancreatic and liver cancer metastasis, the
overexpression of tropomyosin-related kinase B leads to
binding and sequestering Rho GDP dissociation inhibitor,
subsequently activating Rho and its downstream pathways
(Li et al. 2009). Different external molecules also induce
Rho/ROCK activation. In nasopharyngeal carcinoma, N,N0-
dinitrosopiperazine, a carcinogen, increases phosphoryla-
tion of ezrin via Rho/ROCK and PKC pathways, leading to
increased motility and invasion (Tang et al. 2011).
Rho/ROCK activity can also be spatially regulated, in
particular, during cancer cell migration. In pancreatic
ductal adenocarcinoma, RhoA is spatially regulated to the
rear and leading edges of cells, leading to cancer cell
invasion (Timpson et al. 2011); in brain and breast tumor
cells, a RhoA-specific guanine nucleotide exchange factor,
Syx, moves to the membrane, where it activates RhoA and
downstream effector Dia1 and suppresses ROCK activity,
resulting in polarized cancer cell migration (Dachsel et al.
2013); and NG2, a membrane proteoglycan, promotes
amoeboid invasiveness of carcinoma cells through the
activation of Rho (Pankova et al. 2012).
Association Between ROCK Polymorphisms
and Cancer Development
To investigate the role of ROCKs in cancer, identifying
mutated genes and evaluating their potential risks are
important steps. More than 600 somatic coding mutations
in both ROCK genes have been identified in human cancer
genomes originating from human cancer cell lines and
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primary tumors (http://cancer.sanger.ac.uk/cosmic/
search?q=ROCK1) (http://cancer.sanger.ac.uk/cosmic/
search?q=ROCK2). In addition, several thousands of sin-
gle nucleotide polymorphisms (SNPs) of ROCK1 and
ROCK2 genes have been identified (www.ncbi.nlm.nih.
gov/snp/?term=ROCK1) (www.ncbi.nlm.nih.gov/snp/
?term=ROCK2). The role and impact of these mutations
and SNPs in cancer progression remain largely unclear.
Recent studies have validated some of the mutations and
gene variants, with an emphasis on examining those
affecting the coding sequence of ROCK1 and ROCK2, and
determining their impact on cancer pathogenesis (Table 1).
Three of the somatic ROCK1 mutations, which were
identified in human cancers, have been further analyzed to
determine their functional impact by molecular and cellular
approaches (Lochhead et al. 2010). Among the three
mutations, two lead to premature termination of translation
at Tyr405 and Ser1126 in primary breast cancers, and one
leads to a substitution of proline 1193 with serine in lung
carcinoma. All three mutations increase kinase activity
attributable to the removal of auto-inhibition, promote
contraction, increase motility, and decrease adhesion
(Lochhead et al. 2010). Other mutations, located in the
coiled-coil domain, may affect dimerization, RhoA bind-
ing, and kinase activation, such as Thr431Asn (Kalender
et al. 2010), Asp601Val, and Lys1083Met in ROCK2 (Sari
et al. 2013).
Other studies support a potential contributory role of the
somatic mutations to human cancers by analyzing the
mutation frequency. Two ROCK1 and five ROCK2 poly-
morphisms were found significantly associating with
colorectal cancer development (Sari et al. 2013). ROCK1 is
a candidate gene involved in microsatellite instability
(genetic instability due to problems with DNA mismatch
repair) also correlated with colorectal cancer development
(Alhopuro et al. 2012). Thr431Asn polymorphism of the
ROCK2 gene could be a risk factor for the metastases of
breast cancer (Kalender et al. 2010). ROCK2 was found to
be commonly mutated in non-small cell lung cancer by
whole-exome sequencing (Liu et al. 2012a), and its copy
number and gene expression were increased in malignant
peripheral nerve sheath tumors (Upadhyaya et al. 2012).
ROCK and MicroRNAs
MicroRNAs (miRNA) are small pieces of RNA found
between protein coding genes or embedded within their
introns. These pre-miRNA transcripts are processed into
one or more mature miRNAs of *21 to 22 nucleotides
which then regulate cell processes by binding to the 30
untranslated regions (UTR) of targeted messenger RNA,
leading to mRNA degradation and decreased translational
efficiency. Numerous miRNAs involved in regulating
ROCK1 and ROCK2 expression and activity have been
identified in cancer tissues. The down-regulation of specific
miRNAs is correlated with increased ROCK1 or ROCK2
expression (Table 2). Since the 30 UTRs of ROCK1 and
ROCK2 comprise different sets of miRNA-binding sites,
their expressions can be differently regulated by miRNAs.
ROCK1 was found to be a target of miR-145 (Wan et al.
2014) and miR-124 (An et al. 2013) in glioma, miR-145
(Li et al. 2014a) and miR-340 (Cai et al. 2014; Zhou et al.
2013) in osteosarcoma, miR-148a (Zheng et al. 2011),
miR-135a (Shin et al. 2014) and miR-124 (Hu et al. 2014)
in gastric cancer, miR-186 (Cui et al. 2014) and miR-148a
(Li et al. 2013b) in non-small cell lung cancer cells,
Table 1 ROCK mutations associated with cancers
Isoform Coding mutation Domain Function Association with cancer References
ROCK1 Tyr405* Kinase Activation Breast cancer Lochhead et al.
(2010)
Ser1126* PH Activation Breast cancer Lochhead et al.
(2010)
Pro1193S PH Activation Lung cancer Lochhead et al.
(2010)
Val1309* PH May increase kinase activity Colorectal cancer with
microsatellite instability
Alhopuro et al.
(2012)
ROCK2 Thr431Asn Coiled-
coil
May affect dimerization, Rho binding, and
kinase activation
Breast cancer Kalender et al.
(2010)
Asp601Val Coiled-
coil
May affect dimerization, Rho binding, and
kinase activation
Colorectal cancer Sari et al. (2013)
Lys1083Met Coiled-
coil
May affect dimerization, Rho binding, and
kinase activation
Colorectal cancer Sari et al. (2013)
Increased gene copy
number (2.89)
Increased expression/activation Malignant peripheral nerve
sheath tumor
Upadhyaya et al.
(2012)
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miR146a (Lin et al. 2008) and miR-135a (Kroiss et al.
2015) in prostate cancer, miR-584 (Ueno et al. 2011) in
renal cancer, and miR-1280 (Majid et al. 2012) in bladder
cancer. Decreased expression of the miRNAs in cancer
tissues leads to increased ROCK expression/activity and
increased migration, invasion, or proliferation, which can
be rescued by either overexpression of the miRNAs or
inhibition of ROCK1 by either a ROCK inhibitor (Y27632)
or ROCK1 siRNA molecules (An et al. 2013; Hu et al.
2014; Li et al. 2013b, 2014a; Ueno et al. 2011; Zheng et al.
2011; Zhou et al. 2013). It is worth noting that miRNAs
also target other transcripts in addition to ROCK1, such as
miR-148b and miR-335 targeting multiple genes in breast
cancer (Cimino et al. 2013) and in neuroblastoma cells
(Lynch et al. 2012), respectively. Another example is
miR135a which targets both ROCK1 and ROCK2 as well
as numerous genes involved in cellular movement, cellular
assembly/organization, and cell morphology in prostate
cancer cells (Kroiss et al. 2015).
In addition to those miRNAs interacting with ROCK1,
there are also miRNAs interacting with ROCK2 in cancers,
for instance, miR-139 (Wong et al. 2011), miR-124 (Zheng
et al. 2012) and miR-101 (Zheng et al. 2015) in hepato-
cellular carcinoma, miR-200b/c in cholangiocarcinoma
(Peng et al. 2013), and miR-138 in oral cancer (Jiang et al.
2010). The down-regulation of these miRNAs in cancer
tissues leads to increased ROCK2 levels and increased
invasion, migration, and proliferation. These miRNAs also
target other transcripts in addition to ROCK2, such as
EZH2 with miR-124 (Zheng et al. 2012) and SUZ12 with
miR-200b/c (Peng et al. 2013). Furthermore, there are
miRNAs targeting upstream activators of ROCK, for
instance, miR-126 targets the upstream RhoA, and its
down-regulation in colorectal cancers with metastasis
results in the activation of RhoA/ROCK activity (Li et al.
2013c); miR-26a, which is often amplified in glioblastoma,
targets the cyclin-dependent kinase-associated phosphatase
(KAP, a member of the dual-specificity protein phos-
phatase family and is able to bind multiple cyclin-
dependent kinases), a novel binding partner and activator
of ROCK2; down-regulation of KAP leads to decreased
ROCK2 activity and this, in turn, increases Rac GTPase-
mediated invasion (Li et al. 2015a).
While ROCK mRNAs have been shown to be targeted
by miRNA-mediated degradation as mentioned above,
recent reports also revealed the effects of ROCK signaling
on miRNA expression and function. ROCK1 directly
interacts with and stabilizes the oncogene c-Myc protein
leading to the increased oncomir miR-17–92 cluster
expression in breast cancer and prostate cancer (Liu et al.
2009; Zhang et al. 2014). Inhibition of ROCK activity in
vascular tumor-forming endothelial cells was reported to
alter the global miRNA expression (Stiles et al. 2013).
Moreover, ROCK inhibitors enhance miRNA function by
promoting miRNA-mediated degradation of mRNA tar-
gets; ROCK inhibitors induce a conformational change of
ROCK1 thereby enhancing its binding to the transcription
factor, hepatocyte nuclear factor 4 alpha, leading to
increased transcription of poly(A)-binding protein-inter-
acting protein 2, which enhances poly(A)-shortening of
miRNA-targeted mRNAs and leads to global up-regulation
of miRNA function (Yoshikawa et al. 2015). The general
reduction in miRNA expression and impaired miRNA
processing are commonly observed in human and experi-
mental cancers, suggesting that they may be related to
tumorigenesis (Calin and Croce 2006), hence the effects of
the ROCK inhibitor-induced increase in global miRNA
activity may be valuable for developing novel cancer
therapeutics.
ROCK is a Key Player in Cancer Progression
ROCK and its downstream targets are involved in regu-
lating actin cytoskeleton dynamics, and therefore are
responsible for cell migration and motility. In addition,
they are implicated in diverse biological processes such as
cell junction integrity, cell cycle control, and cell apopto-
sis. Their roles in various processes of cancer progression,
such as tumor invasion/metastasis, proliferation, and
Table 2 Regulation of ROCK1 and ROCK2 by miRNAs
Isoform MiRNA Cancer References
ROCK1 miR-124 Brain An et al. (2013)
Gastric Hu et al. (2014)
miR-135a Gastric Shin et al. (2014)
miR-145 Bone Li et al. (2014a)
Brain Wan et al. (2014)
miR-146a Prostrate Lin et al. (2008)
miR-148a Gastric Zheng et al. (2011)
Lung Li et al. (2013b)
miR-148b Breast Cimino et al. (2013)
miR-186 Lung Cui et al. (2014)
miR-340 Bone Zhou et al. (2013)
miR-335 Brain Lynch et al. (2012)
miR-584 Renal Ueno et al. (2011)
miR-1280 Bladder Majid et al. (2012)
ROCK2 miR-101 Liver Zheng et al. (2015)
miR-124 Liver Zheng et al. (2012)
miR-138 Tongue Jiang et al. (2010)
miR-139 Liver Wong et al. (2011)
miR-200 b/c Liver Peng et al. (2013)
ROCK1 and 2 miR-135a Prostate Kroiss et al. (2015)
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apoptosis/survival, as well as the roles in both cancer and
cancer-associated cells, such as fibroblasts and endothelial
cells, have been extensively explored (Chen et al. 2014;
Kale et al. 2015; Mali et al. 2014; Matsuoka and Yashiro
2014; Morgan-Fisher et al. 2013; Rath and Olson 2012;
Schofield and Bernard 2013). Although ROCK activation
is generally considered to be oncogenic, some studies show
that ROCK functions as a negative regulator in cancer
progression. As a result, the precise role of ROCK in
affecting different types of cancer process is context
defined, specifically depending on cell type and the
microenvironment surrounding a tumor.
ROCK in Tumor Cell Invasion and Metastasis
The role of the Rho/ROCK pathway in tumor cell invasion
and metastasis has been extensively studied since its role in
promoting tumor cell dissemination in vivo was firstly
reported (Itoh et al. 1999). Most studies favor a positive role
of ROCK activation in enhancing tumor cell invasion and
metastasis via direct effects on tumor cell motility and/or
indirect effects on cancer-associated fibroblasts to increase
extracellular matrix stiffness and facilitate cancer cell
movement; inhibiting ROCK by chemical inhibitors leads
to decreased tumor cell invasion and metastasis. Among the
recent studies, Y27632 decreased breast cancer cell inva-
sion/migration in vitro and metastasis in vivo in a mouse
model of human breast cancer metastasis to human bone
(Liu et al. 2009); fasudil or Y27632 decreased invasion and
motility of CaOV3 and SKOV-3 ovarian cancer cell lines
(Jeong et al. 2012; Ogata et al. 2009; Peng et al. 2012);
fasudil suppressed the proliferation, migration, and invasion
of A-549 lung cancer cells (Zhu et al. 2011); Y27632
decreased invasive potential of colon cancer SW620 cells
(de Toledo et al. 2012); and Y27632 suppressed progression
of hepatocellular carcinoma through both direct effects on
the migration and proliferation of hepatocellular carcinoma
and indirect effects on the pro-metastatic microenvironment
by deactivating activated hepatic stellate cells in fatty liver
(Mikuriya et al. 2015). The underlying mechanisms
resulting from ROCK inhibition include reduction of stress
fiber formation and peripheral focal adhesions (Liu et al.
2009), loss of membrane blebbing and re-established
E-cadherin dependent adherent junctions (de Toledo et al.
2012), loss of intracellular cytoskeletal rearrangement
(Ogata et al. 2009), inhibition of the epithelial to mes-
enchymal transition (Castro et al. 2013; de Toledo et al.
2012), and inhibition of proteolytic enzyme expression such
as matrix metalloproteinase 9 and urokinase-type plas-
minogen activator (Jeong et al. 2012).
Contrasting to these studies demonstrating beneficial
effects of ROCK inhibition, several others have shown the
detrimental effects of ROCK inhibition. Y-27632 treatment
activated dormant MCF-7 breast cancer cells through the
disintegration of cell junctions coupled with the loss of
E-cadherin and b-catenin from the cell membrane leading to
increased migration and invasion in both two-dimensional
and three-dimensional substrates (Yang and Kim 2014).
Y27632 also increased the invasion of SW620 colon cancer
cells in three-dimensional collagen matrix, but not in two-
dimensional matrix (Vishnubhotla et al. 2012). In addition,
treatment with Y-27632 in SW480 colon cancer cells also
increased migration associated with dramatically altered
focal adhesions (Adachi et al. 2011).Moreover, inhibition of
ROCK2 through binding to coronin1A/B via its PH domain
was required for neuregulin 1 stimulated scattering of MCF-
7 cells (Rana andWorthylake 2012). Together, these studies
reveal that the contribution of Rho/ROCK signaling to
cancer cell migration varies depending on the cell line tested
and on the surrounding microenvironment.
The contradicting effects of ROCK inhibition on tumor
cell invasion and metastasis can be related to the great
plasticity of cancer cells in their migratory mechanisms and
to the activation of other signaling pathways involved in
cell migration, for instance, Rac GTPase-mediated signal-
ing (Fife et al. 2014; Kale et al. 2015; Li et al. 2015a;
Matsuoka and Yashiro 2014; Prudnikova et al. 2015; Sadok
and Marshall 2014; Yang and Kim 2014). Cancer cells are
able to display different modes of motility which has been
broadly classified as single-cell and collective-cell migra-
tion. Single-cell migration is further subdivided into
elongated mesenchymal and rounded amoeboid types
which have different requirements of molecular signaling.
Cancer cells have also been shown to switch modes of
migration after ROCK inhibition, for instance, from roun-
ded amoeboid type to elongated mesenchymal type in
Y27632 treated gastric cancer cells (Matsuoka et al. 2011).
Drug combinations to simultaneously block several targets
may produce greater anti-metastatic effects: combined
inhibition of ROCK and Rac reduced mesenchymal
motility of Y27632 treated gastric cancer cells (Matsuoka
and Yashiro 2014; Matsuoka et al. 2011); combined inhi-
bition of ROCK and myotonic dystrophy kinase-related
Cdc42-binding kinases (MRCK) inhibited migration and
invasion of lung, breast, melanoma, and pancreatic cancer
cells (Kale et al. 2014, 2015). Finally, the recently devel-
oped new ROCK inhibitors with higher potency than
Y27632 or fasudil may be more effective in blocking tumor
cell invasion and metastasis (Sadok et al. 2015).
ROCK in Tumor Cell Proliferation
and Angiogenesis
Similar to its activity in tumor cell invasion and metastasis,
a majority of studies support a positive role of ROCK in
tumor growth through regulating cell proliferation and
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angiogenesis. Numerous reports indicate that ROCK inhi-
bition decreases tumor cell proliferation and angiogenesis
(Chen et al. 2014). Through its well-established role in
promoting stress fiber formation, ROCK promotes fibro-
nectin matrix assembly, cell adhesion, and colonization of
metastatic kidney tumor cells (Knowles et al. 2015).
Y-27632 treatment in melanoma significantly changed 94
gene transcripts, many of which are involved in tumor
initiation and progression, indicating that ROCK signaling
also contributes to the tumor transcriptome in addition to
its well-established role in the regulation of F-actin
dynamics (Spencer et al. 2011). In lung cancer, fasudil
treatment inhibited the growth of 95D lung carcinoma cells
(Yang et al. 2010); it also significantly attenuated angio-
genesis as it inhibited lung carcinoma-conditioned
endothelial cell proliferation and in vivo invasive ability by
causing stress fiber fracture and breakage (Zhang et al.
2012). Moreover, ROCK inhibition may also decrease
tumor cell proliferation by preventing the activation of
oncogenes. ROCK phosphorylates the oncogene c-Myc at
T58 and/or S62, ensuring higher stability and transcrip-
tional activity of c-Myc in breast cancer (Liu et al. 2009)
and in prostate cancer (Zhang et al. 2014); hence the
inhibition of ROCK lowers c-Myc activity.
ROCK activity plays a critical role in cytokinesis in
centrosomes, the microtubule organization centers govern-
ing chromosome segregation during cell division.
Centrosome abnormality leads to genomic instability, rep-
resenting a common feature of tumor cells. Extra
centrosomes can result in aneuploidy and polyploidy, which
are thought to be tumorigenic. At centrosomes, morgana/
chp-1 directly binds ROCK2 and prevents ROCK2 activa-
tion by nucleophosmin; the down-regulation of morgana in
mice or in patients with atypical chronic myeloid leukemia
leads to increased ROCK2 kinase activity, which results in
centrosome amplification and cytogenetic abnormalities (Di
Savino et al. 2015; Ferretti et al. 2010). In breast cancer cells,
BRCA2 directly binds to nucleophosmin and ROCK2 at
centrosomes; the dysfunction of BRCA2,which accounts for
the majority of heredity breast and ovarian cancer, causes
aberrant centrosome amplification and a high frequency of
multinucleated cells (Wang et al. 2011). While increased
ROCK activity resulted in centrosome abnormality and
genomic instability, ROCK inhibitors were also found to
further increase chromosome instability and induce massive
chromosome segregation errors and suppress T cell leuke-
mia growth through inducing microtubule-dependent
centrosome fragmentation (Oku et al. 2014).
Conversely, ROCK inhibition was also found to increase
cell proliferation in other studies. In colon cancer (Naka-
shima et al. 2010) and pancreatic cancer cells (Nakashima
et al. 2011), treatment with Y-27632 induced cell prolif-
eration. These studies suggest that ROCK negatively
regulates EGF-induced cell proliferation (Nakashima et al.
2010), while EGF first stimulates the activation of the EGF
receptor and subsequently increases cancer cell prolifera-
tion, EGF concurrently induces the activation of ROCK,
which then turns off the activated EGF receptor pathway
via a negative feedback system. Thus, inhibiting ROCK
with Y-27632 prevents the negative feedback, leading to
increased EGF activity and cell proliferation (Nakashima
et al. 2011). Furthermore, ROCK inhibition was reported to
promote cell proliferation through the down-regulation of a
tumor suppressor gene, phosphatase and tension homolog
(PTEN), leading to the up-regulation of Akt phosphoryla-
tion which is essential for cell proliferation and survival
(Fusella et al. 2014; Yang and Kim 2012). Taken together,
ROCK has a general positive role in cancer cell prolifer-
ation in many cell types through promoting actomyosin
cytoskeleton contractility and cell adhesion, cytokinesis,
and activation of oncogenes; though there are some
exceptions in specialized contexts through negative feed-
back on growth factor signaling (for instance, EGF) and
promoting tumor suppressor gene activation (for instance,
PTEN).
ROCK in Tumor Cell Survival and Apoptosis
The investigations of the role of ROCK in tumor cell
survival and apoptosis returned discordant marks. Many
studies have shown that the inhibition of ROCK is bene-
ficial through increasing apoptosis. For example, Y-27632
treatment of cultured melanoma cells decreased tumor cell
invasion and altered cell survival; in addition, the treatment
reduced melanoma tumor volume in tumor-bearing mice
(Routhier et al. 2010). In bladder cancer, fasudil increased
the apoptotic response (Abe et al. 2014). In leukemia,
ROCK1 bound to Erk1/2, and inhibiting ROCK released
Erk1/2, consequently increasing apoptosis (Li et al. 2013a).
In acute myeloid leukemia (AML), ROCK1 depletion by
genetic knockout or ROCK inhibition with H-1152,
Y27632, or fasudil reduced the survival of malignant cells
bearing oncogenic form of KIT, FLT3, and BCR-ABL
through suppressing MLC phosphorylation (Mali et al.
2011). ROCK1 knockdown by siRNA or fasudil treatment
also resulted in increased apoptosis and decreased viability
of primary cells isolated from AML patients (Wermke
et al. 2015).
Other investigations, in contrast, revealed that the inhi-
bition of ROCK promotes tumor cell survival and
chemoresistance, or reduces the apoptotic effects of anti-
carcinogens. Y-27632 treatment in neuroblastoma
increased cell survival and facilitated the development of
chemoresistance to cisplatin due in part to altered expres-
sion of cisplatin resistance genes (Street et al. 2010). In
leukemia, RhoA/ROCK1/PTEN activation was critical to
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apoptosis induced by R-(-)-gossypol acetic acid (AT-101),
a natural cottonseed product that exhibits anti-cancer
activity, but the treatment with Y27632, or down-regula-
tion of ROCK1 with siRNA lowered the effectiveness of
the small molecule inhibitor (Li et al. 2014b). Triptolide,
an active component of a Chinese herbal remedy, induces
apoptosis through caspase-3-mediated ROCK1 activation
and MLC phosphorylation (Liu et al. 2013). Curcumin-
induced apoptosis in ovarian cancer SKOV3 cells in part
through activation of RhoA/ROCK pathway (Yin and Sun
2014). Taken together, these studies indicate that ROCK
activation is anti-apoptotic in many cell types, especially in
leukemia, by intervening oncogenic proliferation and sur-
vival signaling, whereas proapoptotic in other specific
contexts, in particular in mediating apoptotic signaling
triggered by some chemo-drugs or anti-carcinogens.
ROCK in Cancer Stem Cells
Cancer stem cells, also named tumor-initiating cells, repre-
sent a small subpopulation of cancer cells and are recognized
as the root cause behind cancer metastasis and recurrence.
There has been a great deal of interest in expanding cancer
stem cells in vitro for investigating their tumorigenicity.
ROCK inhibition was initially observed to facilitate the
in vitro growth of human embryonic stem cells by inhibiting
dissociation-induced apoptosis, named anoikis, through the
blockage of ROCK/MLC-regulated actomyosin contraction
(Watanabe et al. 2007). Due to the prominent pro-survival
effects of ROCK inhibition, the inclusion of ROCK inhibi-
tors such as Y27632 has become part of standard stem cell
culture protocols for embryonic, somatic, and cancer stem
cells (Castro et al. 2013; Ohata et al. 2012; Tilson et al. 2015;
Watanabe et al. 2007; Zhang et al. 2011). In addition to
promoting survival, ROCK inhibitors also increase prolif-
eration of cancer stem cells, for instance, mouse mammary
epithelial tumor-initiating cells (Castro et al. 2013), and
enhance stem-like phenotypes with increased expression of
related stem cell markers (Ohata et al. 2012; Tilson et al.
2015). ROCK inhibition also cooperates with irradiated
fibroblast feeder cells to induce conditional reprogramming
of normal and tumor epithelial cells from various tissues into
adult stem-like cells (Liu et al. 2012b; Palechor-Ceron et al.
2013; Suprynowicz et al. 2012), or into a progenitor cell-like
phenotype (Saenz et al. 2014), capable of proliferating
indefinitely in vitro. The mechanisms underlying the bene-
ficial effects of ROCK inhibitors in stem cell culture in vitro
are attributed to the blockade of actomyosin hypercontrac-
tion-mediated apoptosis (Castro et al. 2013; Ohata et al.
2012; Tilson et al. 2015; Watanabe et al. 2007; Zhang et al.
2011), the suppression of NOTCH signaling induced dif-
ferentiation (Yugawa et al. 2013), and the limitation of
epithelial to mesenchymal transition (Castro et al. 2013).
In contrast to the well-documented beneficial effects of
ROCK inhibitors in promoting cancer stem cell expansion
in culture, fewer studies have investigated the effects of
ROCK inhibition on cancer stem cell tumorigenicity
in vivo. Increasing ROCK-dependent contractility reduced
adhesion of tumor-initiating cells from primary human
glioblastoma to soft extracellular matrix leading to a
rounded and immotile phenotype with reduced migration
and tissue invasion (Wong et al. 2015). In contrast, RhoA/
ROCK activation in stromal cells surrounding cancer stem
cells increased stiffness of extracellular matrix leading to
increased stem cell adhesion to extracellular matrix and
consequently increased spreading, migration, and prolifer-
ation (Choi et al. 2015; Wong et al. 2015). Similar to the
activation of dormant MCF-7 breast cancer cells by ROCK
inhibition as mentioned above (Yang and Kim 2014),
ROCK inhibition in cancer stem cells may alter the acti-
vation of other signaling pathways involved in regulation
of cytoskeleton, for instance, Rac and Cdc42 GTPase-
mediated signaling activation, therefore increasing
cytoskeletal plasticity and cell adhesion to extracellular
matrix, and integrin-mediated signaling. These ROCK
inhibition-related potential pro-survival and pro-extracel-
lular matrix adhesive effects on cancer stem cells and on
dormant cancer cells represent a risk for cancer cell dis-
semination and metastasis, and therefore need to be
considered to avoid the potential undesirable effects of
ROCK inhibition therapy.
Overlapping and Differential Roles of ROCK
Isoforms in Tumorigenesis
Current research on ROCK function and its clinical
applications as a potential therapeutic target are mainly
dependent on the use of small molecule inhibitors; how-
ever, these inhibitors modulate the activity of both ROCK
proteins. One possible explanation for the apparently
inconsistent roles of ROCK in various cancer processes is
that the two ROCK isoforms have both overlapping and
unique functions, which can even oppose one another in
specialized contexts. We have recently shown the distinct
roles of the ROCK isoforms in mouse embryonic fibrob-
lasts in regulating the actin cytoskeleton under stress
conditions; ROCK1 is involved in MLC phosphorylation,
actomyosin contraction, and disruption of central stress
fibers, while ROCK2 stabilizes the actin cytoskeleton
through cofilin phosphorylation (Shi et al. 2013a, b; Surma
et al. 2014; Wei et al. 2015). Other recent studies have also
revealed functional differences between ROCK1 and
ROCK2 in regulating the actin cytoskeleton and other
cellular functions in non-tumor cells (Chun et al. 2012;
Herskowitz et al. 2013; Lock et al. 2012; Newell-Litwa
et al. 2015).
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In tumor cells, ROCK1 and ROCK2 have recently been
reported to have functional differences in regulating
adhesion, migration, proliferation, and gene expression, but
the underlying mechanisms are not fully understood (Inaba
et al. 2010; Mertsch and Thanos 2014; Montalvo et al.
2013; Rochelle et al. 2013; Vega et al. 2011; Vigil et al.
2012; Wang et al. 2014). In non-small cell lung carcinoma,
suppression of ROCK1 or ROCK2 expression alone was
sufficient to impair anchorage-independent growth (Vigil
et al. 2012). A decreased cell migration rate was observed
with either ROCK1 or ROCK2 knockdown in mouse
pancreatic endothelial cells and angiosarcoma cells, only
ROCK2 knockdown showed reduced phosphorylation of
MLC phosphatase and cofilin (Montalvo et al. 2013). In
retinoblastoma cells, inhibiting ROCK1 with siRNA
increased adhesion and decreased invasive capacity simi-
larly to ROCK inhibition by Y27632, but no effect was
observed after inhibiting ROCK2 by siRNA, possibly due
to a lower expression of ROCK2 than ROCK1 in these
cells (Wang et al. 2014). In glioblastoma cells, knocking
down ROCK1 by shRNA impaired cell migration and
reduced cell proliferation similarly to ROCK inhibition by
Y27632, while in contrast, ROCK2 knockdown increased
cell migration and proliferation (Mertsch and Thanos
2014). In these cells, ROCK1 knockdown also reduced
ROCK2 expression, and not conversely; therefore, ROCK1
knockdown may result in a greater reduction of total
ROCK activity than ROCK2 knockdown (Mertsch and
Thanos 2014). Together, these studies suggest that inhibi-
tion of one ROCK isoform in tumor cells may inhibit
tumorigenicity similarly to ROCK pan-inhibition, but with
less induction of other signaling pathways involved in
cytoskeleton regulation, therefore reducing the potential
undesirable effects of ROCK inhibition therapy as
reviewed above. The functional differences for ROCK1
and ROCK2 in tumor and non-tumor cells could be
explained by their variations in expression levels, subcel-
lular locations, and interaction partners in individual cell
types (Amano et al. 2010a; Morgan-Fisher et al. 2013;
Schofield and Bernard 2013; Shi and Wei 2007). More
investigations on ROCK isoform function in cancer are
required in order to elucidate the underlying mechanisms
of their functional differences and determine the predom-
inant functional isoform in the relevant tumor types.
Promising Potential of ROCK Inhibition in Cancer
Therapy
The most commonly used chemical inhibitors of ROCK are
fasudil (also named HA-1077) (Asano et al. 1987) and
Y27632 (Uehata et al. 1997). Fasudil is the only ROCK
inhibitor used in humans for systemic applications, and was
approved in Japan in 1995 for the prevention and treatment
of cerebral vasospasm after surgery in subarachnoid hem-
orrhagic patients (Shibuya et al. 1992). Hydroxyfasudil is
the main metabolite of fasudil after oral administration, and
H-1152P is another analog of fasudil, both of them are
more potent than fasudil. Because these inhibitors target
the ATP-dependent kinase domain of ROCK1 and ROCK2,
they are non-isoform specific and also inhibit other serine/
threonine kinases such as PKA and PKC at higher con-
centrations (Bain et al. 2007; Davies et al. 2000). These
inhibitors have shown beneficial effects in a variety of
animal disease models including cardiovascular, metabolic,
neurodegenerative, and inflammatory diseases, along with
various types of cancer (Fukumoto and Shimokawa 2013;
Huang et al. 2013; Knipe et al. 2015; Morgan-Fisher et al.
2013; Sawada and Liao 2014; Shi and Wei 2013; Wat-
zlawick et al. 2014). Due to the overall promising results of
ROCK inhibition, considerable interest and efforts have
been devoted to the development of more potent and
selective ROCK inhibitors (Feng and LoGrasso 2014;
Guan et al. 2013) including non-isoform selective
(Tables 3, 4) and isoform selective inhibitors (Table 5).
Among these novel ROCK inhibitors, ripasudil (also
named K-115), a close analog of fasudil, has recently
reached the stage of clinical application: it was approved in
Japan in 2014 for the treatment of glaucoma (Garnock-
Jones 2014).
Development of New ROCK Pan-Inhibitors
and Isoform Selective Inhibitors
The resolution of the crystal structures of ROCK1 com-
plexes with four different ATP-competitive inhibitors (Y-
27632, fasudil, hydroxyfasudil, and H-1152P) is construc-
tive for developing highly selective and more potent
inhibitors (Jacobs et al. 2006). Assisted by structure-guided
design, various screening methods have been employed
toward the identification of novel inhibitors, including
high-throughput library screening (Oh et al. 2013a),
structure-guided and fragment-based screening, which uses
small molecules to represent fragments rather than entire
molecules to find possible molecular interactions (Li et al.
2012), and virtual screening using a computer-aided drug
design strategy (Gong et al. 2010; Mishra et al. 2014; Shen
et al. 2013). Because most of the recently developed novel
inhibitors are still targeting the ROCK ATP pocket, they
are generally not isoform selective (Tables 3, 4).
Efforts have recently been devoted to the development
of ROCK isoform selective inhibitors. Several compounds
with significant selectivity for ROCK2 over ROCK1 have
been reported (Boerma et al. 2008; Feng et al. 2008; Li
et al. 2012) (Table 5). SLx-2119, (also named KD-025),
exhibits IC50 values of 0.105 lM for ROCK2 and 24 lM
Arch. Immunol. Ther. Exp.
123
Table 3 Novel ROCK inhibitors and potential therapeutic implications
Compound Isoform selectivity Therapeutic
Implications
Species Referencesa
SAR-407899 IC50 276 nM for
ROCK1, IC50 102 nM
for ROCK2
Hypertension Rats,
human
tissue
Grisk et al. (2012), Lohn et al. (2009)
Erectile
dysfunction
Rats,
rabbits
Guagnini et al. (2012)
Phase 2
trial
NCT00914277
Chronic kidney
disease
Mice Babelova et al. (2013)
Phase 1
trial
NCT01485900
Azaindole-1 Ki 3.7 nM for ROCK1,
Ki 4.8 nM for ROCK2
Pulmonary
hypertension
Rats Pankey et al. (2012)
Erectile
dysfunction
Rats Lasker et al. (2013)
FSD-C10 Encephalomyelitis Mice Li et al. (2014c)
DW1865 IC50 100 nM for
ROCK1, IC50 20 nM
for ROCK2
Hypertension Rats Oh et al. (2013b)
DL0805 IC50 6.67 lM for
ROCK1
Hypertension Rats Gong et al. (2012)
AMA 0076 IC50 3.7 nM for ROCK1,
IC50 2.3 nM for
ROCK2
Glaucoma Rabbits Van de Velde et al. (2014)
Phase 1
trial
NCT02003547
Phase 2
trial
NCT02136940 NCT01693315
K-115
(Ripasudil)
IC50 51 nM for ROCK1,
IC50 19 nM for
ROCK2
Glaucoma Mice,
rabbits,
monkeys
Isobe et al. (2014), Yamamoto et al. (2014)
Phase 1
trial
Tanihara et al. (2013a)
Phase 2
trial
Tanihara et al. (2013b)
Approved
(Japan)
Garnock-Jones (2014)
AR-12286 Glaucoma Phase 1
trial
Kopczynski et al. (2013)
NCT01250197
Phase 2
trial
Williams et al. (2011)
NCT01330979, NCT01060579, NCT01302249, NCT01474135,
NCT01789736, NCT00902200, NCT01699464, NCT02152774,
NCT02173223
AR-13324 Glaucoma Rabbits,
monkeys
Kiel and Kopczynski (2015), Wang et al. (2015)
Phase 1
trial
Levy et al. (2015)
NCT01997879
Phase 2
trial
Bacharach et al. (2015)
NCT02057575, NCT01528787, NCT01731002
Phase 3
trial
NCT02207621, NCT02246764
Only some most recent studies are included due to space limitation
a Clinical trial identifier numbers can be found in https://clinicaltrials.gov
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Table 4 ROCK inhibitors and potential therapeutic implications in cancers
Compound Inhibitory activity Therapeutic implications Species References
Fasudil Ki 0.4 lM for ROCK Leukemia Human cells, mice Mali et al. (2011), Wermke
et al. (2015)
Brain cancer Human cells, mice Nakabayashi and Shimizu
(2011)
Lung cancer Human cells Zhu et al. (2011)
Ovarian cancer Human cells, mice Ogata et al. (2009)
Liver cancer Human cells Takeba et al. (2012)
Bladder cancer Human cells Abe et al. (2014)
Y-27632 Ki 0.22 lM for ROCK1, Ki
0.30 lM for ROCK2
Leukemia Human cells, mice Burthem et al. (2007), Mali
et al. (2011)
Breast cancer Human cells, mice Liu et al. (2009), Yang and
Kim (2014)
Melanoma Human cells, mice Routhier et al. (2010)
Prostate cancer Human cells, mice Zhang et al. (2014)
Ovarian cancer Human cells Jeong et al. (2012)
H-1152 Ki 1.6 nM for ROCK Breast cancer Human cells, mice Castro et al. (2013)
PT262 IC50 5 lM for ROCK Lung cancer Human cells Tsai et al. (2011)
RKI-1447 IC50 14.5 nM for ROCK1, IC50
6.2 nM for ROCK2
Breast cancer Human cells Patel et al. (2012)
RKI-18 IC50 397 nM for ROCK1, IC50
349 nM for ROCK2
Breast cancer Human cells Patel et al. (2014)
OXA-06 IC50 5 nM for ROCK Lung cancer Human cells Vigil et al. (2012)
DJ4 IC50 5 nM for ROCK1, IC50 50 nM
for ROCK2
Lung cancer, melanoma, pancreatic
cancer, breast cancer
Human cells Kale et al. (2014)
AT13148 IC50 6 nM for ROCK1, IC50 4 nM
for ROCK2
Melanoma Human cells, mice Sadok et al. (2015)
Phase 1 trial Breast, prostate,
ovarian cancer
NCT01585701
CCT129254 IC50 214 nM for ROCK1, IC50
141 nM for ROCK2
Melanoma Human Cells, mice Sadok et al. (2015)
Only some most recent studies are included due to space limitation
Table 5 ROCK isoform selective inhibitors and potential therapeutic implications
Compound Isoform specificity Therapeutic
implications
Species Referencesa
MBPTA (ROCK1) IC50 8.68 lM for ROCK1, IC50 203.2 lM for
ROCK2
Parkinson’s disease Human cells Chong et al. (2014)
KD-025/SLx-2119
(ROCK2)
IC50 24 lM for ROCK1, IC50 0.105 lM for
ROCK2
Cerebral ischemia Mice Lee et al. (2014a)
Rheumatoid arthritis Human cells Zanin-Zhorov et al.
(2014)
Psoriasis vulgaris Phase 1 trial NCT02106195
Phase 2 trial NCT02317627
Compound 24 (ROCK2) IC50 1.69 lM for ROCK1, IC50 0.1 lM for
ROCK2
Human cells Li et al. (2012)
SR3677 (ROCK2) IC50 56 nM for ROCK1, IC50 3 nM for ROCK2 Porcine
tissue
Feng et al. (2008)
CID5056270 (ROCK2) IC50 13 nM for ROCK1, IC50 0.56 nM for ROCK2 Human cells Pireddu et al. (2012)
a Clinical trial identifier numbers can be found on https://clinicaltrials.gov
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for ROCK1, though it is also an ATP-competitive inhibitor
(Boerma et al. 2008). A combined approach using high
concentration biochemical assays and fragment-based
screening assisted by structure-guided design has discov-
ered a novel series of ROCK inhibitors, in which
compound 24 possessed more specificity against ROCK2
(IC50 values of 0.1 lM) over ROCK1 (IC50 values of
1.69 lM) (Li et al. 2012). SR3677 was also more selective
for ROCK2 (IC50 values of *3 nM) over ROCK1 (IC50
values of 56 nM) (Feng et al. 2008).
Novel ROCK inhibitors have been used to study non-
cancer diseases (Tables 3, 5). A benzofuran derivative
MBPTA has shown neuroprotective effects in SH-SY5Y
neuroblastoma cells (Chong et al. 2014). SAR-407899
improved erectile dysfunction in rats and rabbits (Guagnini
et al. 2012) and inhibited renal failure progression in mice
with kidney disease (Babelova et al. 2013). Azaindole-1
improved erectile dysfunction (Lasker et al. 2013) and
promoted vasodilation in pulmonary hypertensive rats
(Pankey et al. 2012). SLx-2119 (KD-025), a highly
ROCK2 specific inhibitor, was tested in mice as a treat-
ment for cerebral ischemia (Lee et al. 2014a). FSD-C10 is a
fasudil derivative and intranasal deliverable, and it exhib-
ited effects on suppressing experimental autoimmune
encephalomyelitis and promoting neuroprotection in mice
(Li et al. 2014c). Other studies have reported blood pres-
sure lowering effects of DW1865 in hypertensive rats (Oh
et al. 2013b), vasorelaxant effects of DL0805 in isolated rat
thoracic aorta (Gong et al. 2012), and intraocular pressure
lowering effects of AMA 0076 (Van de Velde et al. 2014)
and K115 (Isobe et al. 2014) in rabbits and monkeys as a
treatment for glaucoma.
ROCK Inhibitors Broadly Used in Experimental
Cancer Studies
ROCK inhibitors fasudil and Y27632 have been exten-
sively used in studies using cancer cell lines and rodent
cancer models, and significant beneficial effects have been
shown in many types of cancers (Chen et al. 2014; Kale
et al. 2015; Mali et al. 2014; Matsuoka and Yashiro 2014;
Morgan-Fisher et al. 2013; Rath and Olson 2012; Schofield
and Bernard 2013) (Table 4). Recent experimental studies
have further supported fasudil as a drug candidate for
hematological malignancies (Mali et al. 2011; Oku et al.
2014; Wermke et al. 2015), lung cancers (Yang et al. 2010,
2012; Zhang et al. 2012; Zhu et al. 2011), bladder cancer
(Abe et al. 2014), glioma (Nakabayashi and Shimizu 2011),
hepatocellular carcinoma (Takeba et al. 2012), and ovarian
cancer (Ogata et al. 2009). Several novel ROCK inhibitors
were tested as an anti-cancer therapy (Table 4). PT262
caused cytoskeleton remodeling and was more effective
than Y27632 or H-1152 in inhibiting migration of A549
lung carcinoma cells (Tsai et al. 2011). RKI-1447 and RKI-
18 prevented breast cancer cell migration and invasion, and
anchorage-independent colony formation (Patel et al. 2012,
2014). OXA-06 was used to show that anchorage-inde-
pendent growth and matrigel invasion of non-small cell
lung carcinoma cells were ROCK dependent (Vigil et al.
2012). DJ4, a multi-kinase inhibitor of both ROCK and
MRCK, inhibited migration and invasion of lung, breast,
melanoma, and pancreatic cancer cells (Kale et al. 2014).
CCT129254 and AT13148, discovered as ATP-competitive
AKT kinase inhibitors, also potently inhibited both
ROCK1 and ROCK2 activity leading to a collapsed
cytoskeletal phenotype, which was not observed in cells
treated with less potent inhibitors Y27632 or H1152 (Sadok
et al. 2015). The potent inhibition of actomyosin contrac-
tion by CCT129254 and AT13148 dramatically impaired
melanoma cell invasion in culture, and reduced metastasis
of melanoma cells in vivo (Sadok et al. 2015). As a result
of more potent and selective ROCK inhibitors becoming
available, more experimental studies and new screening
strategy are underway to evaluate their potential use in
cancer therapy.
Combinations of ROCK Inhibition with Other Anti-
Cancer Therapies
ROCK inhibition has also been examined as a possible
augmentation to current chemotherapy treatments. In
chronic myeloid leukemia, Y27632 and fasudil added to
the anti-proliferative and pro-apoptotic effects of imatinib,
a tyrosine kinase inhibitor (Burthem et al. 2007; Di Savino
et al. 2015). In ovarian cancer, fasudil and Y27632
enhanced the anti-cancer drug cisplatin efficacy in
inhibiting growth and inducing apoptosis of human cancer
cell lines (Ohta et al. 2012). In malignant glioma, ROCK1
knockdown by shRNA increased the efficacy of nimustine
hydrochloride, an alkylating drug used for glioma patients
in Japan (Inaba et al. 2010). Also in glioma, ROCK2
siRNA worked synergistically with the anti-cancer drug
temozolomide, increasing the induction of apoptosis and
inhibiting the migration of U251 cells (Wen et al. 2014). In
NRAS mutant melanoma, simultaneous inhibition of MEK
and ROCK by anti-cancer drug trametinib and fasudil-in-
duced apoptosis and suppressed growth of established
tumors, at concentrations where the single drugs had little
effect (Vogel et al. 2015). These studies reveal that a
combined therapeutic stratagem of ROCK inhibitors with
classic or new anti-cancer drugs might provide greater anti-
cancer effects while reducing chemoresistance and side
effect.
However, as mentioned above, combining ROCK inhi-
bition with chemotherapeutic agents may lead to enhanced
tumor chemoresistance in some circumstances. For
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example, ROCK inhibition by Y27632 in neuroblastoma
cells resulted in enhanced tumor survival following cis-
platin cytotoxicity (Street et al. 2010). In addition, ROCK
inhibition reduced the favorable effects of several natural
anti-carcinogens: indole-3-carbinol in inhibiting motility in
breast cancer cells (Brew et al. 2009); curcumin in induc-
ing apoptosis in ovarian cancer cells (Yin and Sun 2014);
R-(-)-gossypol acetic acid (Li et al. 2014b); and triptolide
(Liu et al. 2013) in inducing apoptosis in leukemia cells.
Hence these detrimental effects of ROCK inhibitors need
to be considered and should be ruled out while developing
novel anti-cancer therapies incorporating ROCK inhibitors.
Clinical Implications of ROCK Inhibitors
for Cancers and Non-Cancer Diseases
Despite the significant promise achieved from experimen-
tal studies of merging ROCK inhibition into therapeutic
strategies, there is only one reported clinical trial using
ROCK inhibitors in cancer treatment: AT13148 in phase 1
clinical trial initiated in 2012 for the treatment of advanced
solid tumors (ClinicalTrials.gov identifier NCT01585701).
AT13148 also inhibits several members of AGC kinase
family including AKT and PKA (Sadok et al. 2015). Of the
four most used ROCK inhibitors (Y-27632, fasudil,
hydroxyfasudil, and H-1152P), fasudil is the only one
approved for the treatment of vasospasm after subarach-
noid hemorrhage (Shibuya et al. 1992), and has been used
in clinical studies primarily for the treatment of cardio-
vascular diseases (Shi and Wei 2013). Current clinical
trials for fasudil found on ClinicalTrials.gov include
atherosclerosis (NCT00120718, NCT00670202), Rey-
naud’s phenomenon (NCT00498615), diabetes
complications (NCT01823081), and neuronal disease
(NCT01935518). Clinical trials using novel ROCK inhi-
bitors have mainly been conducted for cardiovascular
disease and eye disease (Tables 3, 5). SAR-407899 has
been used to treat kidney disease (NCT01485900) and
erectile dysfunction (NCT00914277). SLx-2119 (KD-025)
has been used to treat psoriasis vulgaris (NCT02106195)
and examines the response in autoimmune disease (Zanin-
Zhorov et al. 2014). Several clinical studies have been
performed to treat glaucoma, ocular hypertension, and eye
disease including AMA0076 in phase 1 (NCT02003547)
and phase 2 trials (NCT01693315, NCT02136940), AR-
12286 in phase 1 (Kopczynski et al. 2013) (NCT01250197)
and phase 2 trials (Williams et al. 2011) (NCT01330979,
NCT01060579, NCT01302249, NCT01474135, NCT017
89736, NCT00902200, NCT01699464, NCT02152774,
NCT02173223), AR-13324 in phase I (Levy et al. 2015)
(NCT01997879) and phase 2 trials (Bacharach et al. 2015)
(NCT02057575, NCT01528787, NCT01731002). After
phase 3 clinical trials, Ripasudil (K-115) was approved for
glaucoma in Japan in 2014 (Garnock-Jones 2014). Given
the accumulated indexes of safety and efficiency from
fasudil and some novel ROCK isoform-specific inhibitors
in clinic trials, the application prospect of anti-cancer drugs
targeting ROCK is exhilarating; we expect ROCK inhibi-
tors will become valuable anti-cancer members in the near
future and will make contributions to reducing tumor
growth, decreasing metastasis, and improving disease
outcome.
Conclusions and Future Direction
The ROCK proteins contribute to a broad range of cellular
functions with their main impact on the regulation of many
cytoskeletal-associated proteins. Accumulating evidences
have been showing that ROCK signaling is critically
responsible, at least in part, for many important cancer-
associated phenotypes. There is an increasing interest in
targeting ROCK signaling in cancer therapeutics, espe-
cially in obstructing tumor cell invasion, metastasis, tumor
growth, angiogenesis, cancer-associated alterations of
extracellular matrix, and hematological malignancies.
Although the ROCK inhibitor fasudil has been available in
clinical application for 20 years, it has not yet been used in
cancer treatment, and the number of clinical trials for
human cancer is still limited.
There are a number of challenges in translating updating
knowledge of ROCK signaling into anti-cancer therapy;
the current information on the role of ROCK signaling in
tumorigenicity is still incomplete, in particular, the mech-
anisms underlying both the positive and negative roles of
ROCK in regulating migration, proliferation, apopto-
sis/survival, and chemoresistance of tumor cells, including
primary tumor cells, tumor stem cells, and dormant tumor
cells, remain unclarified. Nevertheless, it has become
progressively clear that the consequences of ROCK inhi-
bition and the induction of compensatory signaling
pathways, especially those involving in cytoskeleton reg-
ulation, largely depend on the tumor cell type, cell context,
and the microenvironment; therefore, the complexity in
evaluating the application of ROCK inhibitors is aug-
mented. Combined inhibition of ROCK and compensatory
signaling could be useful to avoid potential undesirable
effects of ROCK inhibition. Furthermore, the first genera-
tion of ROCK inhibitors including fasudil shows non-
specific inhibitory effects on other kinases, so it may cause
off-target effects. Many more potent and selective ROCK
inhibitors have recently been developed, some of them may
show promising potential in cancer therapy in the near
future. It is worth noting that the combination therapy of
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ROCK inhibitors and other anti-cancer drugs produces
greater anti-cancer effects while resistance to single agent
is reduced.
There is increased agreement that ROCK1 and ROCK2
have both redundant and non-redundant functions, and
isoform-specific inhibition may therefore elicit different
biological effects. Although the majority of currently
available ROCK inhibitors are suitable initial tools for
investigating the role of ROCK in cancer, their limitation
in mechanistic studies is unavoidable due to their non-
isoform selective nature. Additionally, ROCK1 and
ROCK2 expression and/or activity can be separately reg-
ulated by numerous factors, which either positively or
negatively modify their catalytic activity and/or subcellular
localization. Moreover, there are an increased number of
somatic mutations and miRNAs being discovered and
evaluated for their differing impacts on ROCK isoform
expression and activity. Hence, in order to develop iso-
form-specific targeting strategy for cancer therapy, it is
necessary to understand the different functions of each
ROCK isoform in cancer pathophysiology and ascertain the
major functional isoform in specific tumor types; conse-
quently, it will reduce toxic and undesirable effects than
pan-inhibition in clinic application. Recently developed
ROCK1 and ROCK2 isoform-specific genetically modified
mouse models have offered a unique opportunity to ana-
lyze in vivo physiological and pathological functions of
ROCK1 and ROCK2 (Lee et al. 2014b; Rikitake et al.
2005; Shi et al. 2011; Shimizu et al. 2005, 2013; Soliman
et al. 2015; Thumkeo et al. 2003; Zhang et al. 2006),
including cancer development and progression (Mali et al.
2011; Samuel et al. 2011). Some novel isoform selective
inhibitors are becoming commercially available and will
serve as valuable tools for further dissecting the roles of
ROCK1 and ROCK2 in cancer and other diseases.
Importantly, the continuation of significant progress in
basic and preclinical researches will undoubtedly move
ROCK isoform inhibitors to future clinical practice.
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